GlassScriptPhysician profile
Erik Wells
NPI 1528509312
$3,131.63
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,101 · 2022: $1,130 · 2023: $882 · 2024: $18.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.55 | 2021-2023 | |
| Novo Nordisk INC | $342.34 | 2021-2023 | Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $292.37 | 2021-2023 | |
| Pfizer INC. | $246.27 | 2022-2023 | |
| Lilly USA, LLC | $197.77 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.96 | 2021-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $145.65 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.09 | 2021-2023 | Jardiance |
| Amgen INC. | $106.33 | 2021-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $105.08 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $70.88 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $66.17 | 2022-2023 | Prehevbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $66.02 | 2021-2022 | |
| Glaxosmithkline, LLC. | $64.68 | 2021-2024 | Trelegy Ellipta |
| Genentech USA, INC. | $54.91 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $54.84 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $50.21 | 2021 | |
| Halozyme INC | $46.94 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.57 | 2022 | |
| Exact Sciences Corporation | $42.60 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $41.84 | 2021 | |
| Idorsia Pharmaceuticals US INC | $40.65 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $40.13 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $36.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.19 | 2021-2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $36.16 | 2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $34.66 | 2022 | |
| Abbott Laboratories | $34.46 | 2022 | |
| Daiichi Sankyo INC. | $27.02 | 2023 | Injectafer |
| Dynavax Technologies Corporation | $20.59 | 2022 | |
| Si-Bone, INC. | $19.60 | 2023 | |
| Merck Sharp & Dohme LLC | $16.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.12 | 2021 | |
| Corcept Therapeutics | $15.67 | 2023 | Korlym |
| Almatica Pharma LLC | $14.58 | 2021 | |
| Nabriva Therapeutics, Plc | $13.43 | 2021 | |
| Clarus Therapeutics INC. | $13.05 | 2021 | |
| Vistapharm, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.